Dave Asprey's 'wellness stacking' peptide claims: what the science says

What's this video probably claiming?

Dave Asprey has built a brand around the idea that combining multiple interventions simultaneously produces effects greater than the sum of their parts. In a video tagged under peptides and "wellness stacking," he's almost certainly pitching a curated protocol of bioactive peptides, possibly including BPC-157 for recovery, CJC-1295 and ipamorelin for growth hormone stimulation, GHK-Cu for skin and tissue repair, and semax or selank for cognitive enhancement. The framing is likely that strategic layering of these compounds is the logical endpoint of biohacking. He may be suggesting that aging is a problem with a pharmaceutical workaround, and that self-directed peptide stacking is both safe and effective for longevity. Expect confident claims about cellular regeneration, anti-aging, and performance without much qualification around regulatory status or clinical data gaps.

What does the science actually show?

The honest answer is: it depends enormously on which peptide you're asking about, and the human data is often thin. BPC-157 has genuine mechanistic interest, with animal studies showing accelerated tendon and gut healing (Sikiric et al., 2018, Current Pharmaceutical Design), but there are zero published randomized controlled trials in humans. CJC-1295 does elevate GH and IGF-1 levels in humans at doses around 1-2 mcg/kg, confirmed in a phase 2 trial (Teichman et al., 2006, Journal of Clinical Endocrinology and Metabolism), but the jump from "raises IGF-1" to "extends lifespan" is not supported. GHK-Cu shows in vitro collagen synthesis activity, but in vivo human trials for systemic anti-aging are essentially nonexistent. Semax has some Russian clinical data in stroke recovery contexts, not in healthy longevity populations. Stacking these without clinical guidance multiplies unknown interactions, not proven benefits.

Where does the social media noise diverge from clinical reality?

The biggest divergence is the implicit suggestion that stacking is additive or synergistic by design. No published study has evaluated multi-peptide stacking protocols of the type Asprey promotes. Individual peptides target different receptor systems, and combining them without monitoring can create unpredictable endocrine feedback. Growth hormone secretagogues like ipamorelin and CJC-1295 combined raise IGF-1, and chronically elevated IGF-1 is associated with increased cancer risk in epidemiological data (Renehan et al., 2004, Lancet, meta-analysis of 21 studies). That's not a reason to panic, but it's a real consideration Asprey's framing tends to skip. Additionally, most peptides discussed in biohacking content are not FDA-approved for the uses described. In 2023, the FDA placed BPC-157 and several other peptides on its "difficult to compound" list, restricting their use in compounded preparations. That regulatory context rarely appears in wellness stacking content.

What should you actually know?

Peptide therapy is a legitimate area of clinical research, and some protocols are used in supervised medical settings with real rationale. The problem is the gap between what animal models or early-phase trials show and what biohacking influencers promise. If you're interested in peptides, the conversation should start with a physician who can assess your baseline IGF-1, cortisol, and pituitary function before anything is introduced. Self-directed stacking based on TikTok protocols is genuinely risky, not because peptides are inherently dangerous, but because combinations affect hormone axes that interact in ways even endocrinologists find complex. Asprey is not a licensed medical professional. His personal experimentation is not a substitute for clinical data. The regulatory status of compounded peptides in the US changed materially in 2023-2024, and purchasing these compounds without a prescription from a licensed provider puts consumers in a legally and medically ambiguous position that no TikTok caption adequately discloses.